Skip to content

EPRX

Eupraxia Pharmaceuticals, Inc.

NASDAQ · Healthcare · Biotechnology · CA

$6.76
−1.74%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
-45.5%
EBIT
-64.8%
EPS
-19.3%
Free cash flow
-18.4%
Operating cash flow
-17.7%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
-55.0%

Three-year CAGR

Revenue
—
EBITDA
-53.6%
EBIT
-42.3%
Net income
-51.3%
EPS
-35.5%
Free cash flow
+1.6%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026